in this issue
Regions :: Western Europe :: U.K.
GSK and Lonza Sign Manufacturing Deal
September 8, 2010 | Deepti Ramesh
Lonza says it has entered into an agreement with GlaxoSmithKline (GSK; London) under which Lonza will support the ongoing development of GSK’s biopharmaceutical pipeline by supplying manufacturing capacity for five early stage monoclonal antibodies. Lonza will initially manufacture clinical trial batches of five compounds currently in Phase 1 and 2 for GSK, under the terms of the deal. Lonza will also provide access to flexible capacity to enable GSK to respond to future demand dependent upon progression of molecules through late stage development and...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be: